Gestational diabetes mellitus (GDM) is any degree of glucose intolerance with onset or first recognition during pregnancy.
Hyperglycemia in pregnancy may be suggested by the presence of glycosuria, a fetus that is large for date, or polyhydramnios.
Overt diabetes mellitus may be found in women presenting with risk factors for type 2 diabetes during the first prenatal visit (before 13 weeks of gestation).
Overweight or obese women with gestational diabetes mellitus (GDM) may fare well with metformin treatment, which is reported in a recent study to safely and effectively prevent excessive and promote adequate gestational weight gain (GWG) independent of age, body mass index (BMI) and timing of GDM diagnosis, among others.
Women who conceive singleton pregnancies following assisted reproductive technology (ART) may have a higher risk of developing gestational diabetes than those who conceive spontaneously, according to results of a systematic review and meta-analysis presented at EASD 2019.
Gestational diabetes and abnormal glucose levels in pregnancy, as determined with an oral glucose challenge test (OGCT) at 24–28 weeks gestation, could signal a future risk of cardiovascular disease (CVD)*, according to a recent study.
Metformin continues to protect high-risk individuals from developing type 2 diabetes (T2D) over 15 years, especially among those with higher glycaemic status at baseline and women reporting a history of gestational diabetes mellitus (GDM), according to long-term results from DPP/DPPOS*.
Eating vegetable and protein before carbohydrate attenuated postprandial glucose response in healthy Asian adults, according to the PATTERN* study, suggesting that behavioural change in eating sequence may be a potential strategy for modulating glycaemic response.
The cardiovascular (CV) benefits of the SGLT2* inhibitor dapagliflozin extend across a broad spectrum of patients with type 2 diabetes (T2D) and high CV risk, in particular those with heart failure with reduced ejection fraction (HFrEF), reports a subanalysis of the DECLARE-TIMI 58 trial presented at ACC.19 Annual Scientific Session.
Individuals with type 2 diabetes (T2D) who are prescribed an SGLT2* inhibitor may have a reduced risk for developing gout compared with those who are prescribed a GLP-1** receptor agonist, according to a study from the US.
Bariatric surgery is beneficial to nondiabetic Asian patients with obesity, delivering sustained weight loss in addition to normalizing sugar levels and insulin resistance within 1–3 years of the procedure, as reported in a Singapore study.
Sleep disorder in nonstandard shift workers appears to contribute to more severe hypogonadal symptoms and lower testosterone levels when compared with daytime workers and nonstandard shift workers without sleep disorder, according to a study.
Markedly different blood glucose responses and postexercise profiles are associated with fasting morning resistance exercise (RE) compared with afternoon RE in individuals with type 1 diabetes (T1D), a recent study has shown.